MetaCap

Iambic Therapeutics (IAM) vs Solid Biosciences (SLDB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Solid Biosciences is the larger company by market cap ($697.6 million vs $621.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IAM-30.67%SLDB+8.89%
+36%-7%-50%
Oct 15, 20261 yearNov 20, 2026
IAM-44.94%SLDB+13.02%
+28%-17%-61%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IAM versus SLDB key metrics
MetricIAMSLDB
Share price$13.11$6.25
Market cap$621.42M$697.57M
1-day change-8.06%-2.95%
YTD return—+10.82%
1-year return—+32.98%
5-year return—-77.78%
EPS (TTM)$-2.69$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-174.32M
52-week high$25.00$11.45
52-week low$9.60$4.65
Distance from 52-week high-47.56%-45.41%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+107.86%+199.36%
Average volume714.92K1.30M
Shares outstanding47.40M111.61M
Employees171121
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

About Solid Biosciences

SLDB stock →

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees

IAM vs SLDB FAQ

Which is bigger, Iambic Therapeutics or Solid Biosciences?

Solid Biosciences (SLDB) is larger, with a market capitalization of $697.57M compared with $621.42M for Iambic Therapeutics (IAM).

Are Iambic Therapeutics and Solid Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons